Found 136 clinical trials
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
- 0 views
- 08 Aug, 2021
- 1 location
Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab
The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of ZW25 in combination with docetaxel in participants with human epidermal growth factor
- 0 views
- 21 Nov, 2021
- 22 locations
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
epidermal growth factor receptor-2 (HER-2) positive primary breast cancer.
- 0 views
- 25 Jan, 2021
- 1 location
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
. Eligible patients include those with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-positive breast cancer.
- 0 views
- 01 Jul, 2021
- 15 locations
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
advanced or metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer and HER2-positive advanced breast cancer with liver metastasis.
- 128 views
- 17 Jul, 2021
- 69 locations
MEtronomic TrEatment Option in Advanced bReast cAncer
This is a multi-center, randomized phase II trial that will randomise women with ER-positive, HER2-negative (Human Epidermal Growth factor Receptor 2-negative) metastatic or locally relapsed
- 58 views
- 24 Jan, 2021
- 24 locations
A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
combination with abemaciclib (VERZENIO) in participants with advanced estrogen-receptor positive, human epidermal growth factor receptor-2 negative (ER+/HER2-) breast cancer.
- 2 views
- 27 Nov, 2021
- 6 locations
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
-negative breast cancer (TNBC), non-squamous non-small-cell lung cancer (NSCLC), estrogen receptor-positive breast cancer, progesterone receptor-positive breast cancer and human epidermal growth factor 2
- 0 views
- 24 Nov, 2021
- 5 locations
Combined Immunotherapies in Metastatic ER+ Breast Cancer
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for
- 0 views
- 11 Jul, 2021
- 5 locations
Elacestrant in Preoperative Setting a Window of Opportunity Study
Estrogen Receptor-positive (ER+) and Human Epidermal Growth Factor Receptor 2-negative (HER2-negative) early breast cancer (BC) amenable to surgery.
- 0 views
- 20 Jun, 2021
- 4 locations